TY - JOUR
T1 - Cardiorenal Protection
T2 - Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
AU - Nagahisa, Taichi
AU - Saisho, Yoshifumi
N1 - Funding Information:
The authors thank Dr. Wendy Gray, self-employed, for editing the manuscript. No funding or sponsorship was received for this study or publication of this article. Publication fee of this article was waived by the publisher. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Yoshifumi Saisho received honoraria from Takeda Pharmaceutical Co. Ltd., Japan and Nippon Boehringer Ingelheim Co. Ltd., Japan and a grant from AstraZeneca K.K., Japan not related to the submitted work. Taichi Nagahisa has nothing to disclose. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D). These observed benefits do not seem to correlate with the glucose-lowering effect, and the underlying mechanism is being intensively investigated. Given the results from recent studies, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend that patients with T2D and clinical cardiovascular disease (CVD) with inadequate glucose control despite treatment with metformin should receive an SGLT2 inhibitor or GLP-1 receptor agonist. In this review we summarize the results of recent cardiovascular outcome trials and discuss the potential clinical advantage of SGLT2 inhibitors and GLP-1 receptor agonists. We also present practical implications of these glucose-lowering agents for reducing the risk of adverse cardiovascular events and progressive renal comorbidity in patients with T2D and CVD.
AB - Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D). These observed benefits do not seem to correlate with the glucose-lowering effect, and the underlying mechanism is being intensively investigated. Given the results from recent studies, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend that patients with T2D and clinical cardiovascular disease (CVD) with inadequate glucose control despite treatment with metformin should receive an SGLT2 inhibitor or GLP-1 receptor agonist. In this review we summarize the results of recent cardiovascular outcome trials and discuss the potential clinical advantage of SGLT2 inhibitors and GLP-1 receptor agonists. We also present practical implications of these glucose-lowering agents for reducing the risk of adverse cardiovascular events and progressive renal comorbidity in patients with T2D and CVD.
KW - Cardiovascular outcome
KW - Glucagon-like peptide-1
KW - Sodium-glucose cotransporter-2
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85071420519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071420519&partnerID=8YFLogxK
U2 - 10.1007/s13300-019-00680-5
DO - 10.1007/s13300-019-00680-5
M3 - Review article
AN - SCOPUS:85071420519
SN - 1869-6953
VL - 10
SP - 1733
EP - 1752
JO - Diabetes Therapy
JF - Diabetes Therapy
IS - 5
ER -
